
亚太地区婴儿、儿童和孕产妇益生菌补充剂市场预测至 2028 年 – COVID-19 影响和区域分析 – 按形式(胶囊和软胶囊、软糖、液体等)和最终用户(婴儿和幼儿、儿童和产妇)
No. of Pages: 92 | Report Code: BMIRE00027129 | Category: Consumer Goods
No. of Pages: 92 | Report Code: BMIRE00027129 | Category: Consumer Goods
亚太地区婴幼儿和孕产妇益生菌补充剂市场预计将从2022年的2.0182亿美元增长到2028年的3.4665亿美元;预计 2022 年至 2028 年复合年增长率为 9.4%。
许多著名的制造商益生菌正在投资研发,为婴儿和孕妇开发可靠且有科学支持的益生菌补充剂。此外,他们正在进行研究,以更深入地了解益生菌对婴儿、儿童和孕妇的益处。发表在《微生物》杂志上的新研究表明,在怀孕后期或哺乳期和母乳喂养期间补充益生菌可以降低乳腺炎的风险。同样,2019 年 4 月,主要食品和营养成分制造商帝斯曼 (DSM) 进行了一项研究,探讨补充益生菌对减少母乳喂养婴儿绞痛的影响。帝斯曼的全资子公司 BioCare 资助了这项研究,并在 4 至 12 周的母乳喂养婴儿身上使用了益生菌菌株,即鼠李糖乳杆菌和罗伊氏乳杆菌,为期 28 天。研究发现,补充益生菌的母乳喂养的婴儿患绞痛的机会较少。整体哭闹时间减少了 163 分钟。
随着婴幼儿和孕产妇益生菌产品需求的不断增长,制造商正在创新其产品产品以增加客户群并增加收入。他们正在推出方便的益生菌输送形式,例如滴剂、棒剂、袋剂、软糖和粉末,以方便婴儿和幼儿食用。这些方便的益生菌补充剂递送形式在亚太地区获得了高度认可。因此,此类研发活动和不断增长的益生菌补充剂研究预计将在预测期内推动婴儿、儿童和孕产妇益生菌补充剂市场的增长。
借助新功能和技术,供应商可以吸引新客户并扩大其在新兴市场的足迹。这一因素可能会推动亚太地区婴儿、儿童和孕产妇益生菌补充剂市场在预测期内以显着的复合年增长率增长。
p>
< span>
亚太地区婴儿、儿童和孕产妇益生菌补充剂市场分为形式、最终用户和国家/地区。根据形式,市场分为胶囊和软胶囊、软糖、液体等。根据最终用户,市场分为婴幼儿、儿童和孕产妇。按国家/地区划分,亚太地区婴儿、儿童和孕产妇益生菌补充剂市场分为中国、日本、澳大利亚、新西兰和亚太地区其他地区。
p>
亚太地区婴儿、儿童和孕产妇益生菌补充剂市场 -提及的公司
拜耳公司、雀巢公司SA、BioGaia AB 和 Nordic Naturals 是亚太地区婴儿、儿童和孕产妇益生菌补充剂市场的几家主要公司。
Strategic insights for Asia Pacific Infant, Child, and Maternal Probiotic Supplements involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
Report Attribute | Details |
---|---|
Market size in 2022 | US$ 201.82 Million |
Market Size by 2028 | US$ 346.65 Million |
Global CAGR (2022 - 2028) | 9.4% |
Historical Data | 2020-2021 |
Forecast period | 2023-2028 |
Segments Covered |
By 形式
|
Regions and Countries Covered | 亚太地区
|
Market leaders and key company profiles |
The regional scope of Asia Pacific Infant, Child, and Maternal Probiotic Supplements refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Asia Pacific Infant, Child, and Maternal Probiotic Supplements Market is valued at US$ 201.82 Million in 2022, it is projected to reach US$ 346.65 Million by 2028.
As per our report Asia Pacific Infant, Child, and Maternal Probiotic Supplements Market, the market size is valued at US$ 201.82 Million in 2022, projecting it to reach US$ 346.65 Million by 2028. This translates to a CAGR of approximately 9.4% during the forecast period.
The Asia Pacific Infant, Child, and Maternal Probiotic Supplements Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Infant, Child, and Maternal Probiotic Supplements Market report:
The Asia Pacific Infant, Child, and Maternal Probiotic Supplements Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Infant, Child, and Maternal Probiotic Supplements Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Infant, Child, and Maternal Probiotic Supplements Market value chain can benefit from the information contained in a comprehensive market report.